Call for EJIM Editor in Chief

Submitted by Aneta on 2 March 2026 - 15:11

We are pleased to announce that we opened the Call for the position of Editor-in-Chief of the European Journal of Internal Medicine, EJIM.
The Editor-in-Chief will assume responsibility for the scientific leadership and strategic development of the journal for a six-year term, beginning in January 2027.
EFIM seeks an internationally recognised expert in Internal Medicine with a strong academic background, editorial experience, and a clear vision for the continued growth and impact of EJIM.
The deadline for applications is 31 May 2026.

Draft concept paper on the development of a reflection paper on the non-clinical development and evaluation of microbiome-based medicinal products

Submitted by Anonymous (not verified) on 2 March 2026 - 12:19

Draft concept paper on the development of a reflection paper on the non-clinical development and evaluation of microbiome-based medicinal products

Human medicines European public assessment report (EPAR): Nemluvio, nemolizumab, Date of authorisation: 12/02/2025, Revision: 5, Status: Authorised

Submitted by Anonymous (not verified) on 2 March 2026 - 11:35

Human medicines European public assessment report (EPAR): Nemluvio, nemolizumab, Date of authorisation: 12/02/2025, Revision: 5, Status: Authorised

Human medicines European public assessment report (EPAR): Azomyr, desloratadine, Date of authorisation: 15/01/2001, Revision: 55, Status: Authorised

Submitted by Anonymous (not verified) on 2 March 2026 - 11:15

Human medicines European public assessment report (EPAR): Azomyr, desloratadine, Date of authorisation: 15/01/2001, Revision: 55, Status: Authorised

Human medicines European public assessment report (EPAR): Nexium Control, esomeprazole, Date of authorisation: 26/08/2013, Revision: 21, Status: Authorised

Submitted by Anonymous (not verified) on 2 March 2026 - 9:55

Human medicines European public assessment report (EPAR): Nexium Control, esomeprazole, Date of authorisation: 26/08/2013, Revision: 21, Status: Authorised

Human medicines European public assessment report (EPAR): Xbonzy, denosumab, Date of authorisation: 17/11/2025, Revision: 1, Status: Authorised

Submitted by Anonymous (not verified) on 2 March 2026 - 9:52

Human medicines European public assessment report (EPAR): Xbonzy, denosumab, Date of authorisation: 17/11/2025, Revision: 1, Status: Authorised

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Latest Newsletters

More
randomness